Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1986 2
1988 1
1989 3
1990 4
1991 3
1992 1
1993 2
1994 5
1995 2
1996 6
1998 3
1999 4
2000 7
2001 5
2002 7
2003 12
2004 4
2005 11
2006 11
2007 9
2008 10
2009 4
2010 8
2011 11
2012 13
2013 11
2014 15
2015 11
2016 10
2017 10
2018 13
2019 14
2020 16
2021 15
2022 14
2023 12
2024 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

278 results

Results by year

Filters applied: . Clear all
Page 1
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Anzueto A, et al. Among authors: bengtsson t. Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. Am J Respir Crit Care Med. 2023. PMID: 37364283 Free PMC article. Clinical Trial.
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.
Donohue JF, Rheault T, MacDonald-Berko M, Bengtsson T, Rickard K. Donohue JF, et al. Among authors: bengtsson t. Int J Chron Obstruct Pulmon Dis. 2023 Jul 28;18:1611-1622. doi: 10.2147/COPD.S413436. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 37533771 Free PMC article. Review.
Hepatic Innervations and Nonalcoholic Fatty Liver Disease.
Adori M, Bhat S, Gramignoli R, Valladolid-Acebes I, Bengtsson T, Uhlèn M, Adori C. Adori M, et al. Among authors: bengtsson t. Semin Liver Dis. 2023 May;43(2):149-162. doi: 10.1055/s-0043-57237. Epub 2023 May 8. Semin Liver Dis. 2023. PMID: 37156523 Free PMC article. Review.
Adrenoceptors in white, brown, and brite adipocytes.
Evans BA, Merlin J, Bengtsson T, Hutchinson DS. Evans BA, et al. Among authors: bengtsson t. Br J Pharmacol. 2019 Jul;176(14):2416-2432. doi: 10.1111/bph.14631. Epub 2019 Apr 7. Br J Pharmacol. 2019. PMID: 30801689 Free PMC article. Review.
Mirabegron: potential off target effects and uses beyond the bladder.
Dehvari N, da Silva Junior ED, Bengtsson T, Hutchinson DS. Dehvari N, et al. Among authors: bengtsson t. Br J Pharmacol. 2018 Nov;175(21):4072-4082. doi: 10.1111/bph.14121. Epub 2018 Jan 18. Br J Pharmacol. 2018. PMID: 29243229 Free PMC article. Review.
The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis.
Talamonti E, Davegardh J, Kalinovich A, van Beek SMM, Dehvari N, Halleskog C, Bokhari HM, Hutchinson DS, Ham S, Humphrys LJ, Dijon NC, Motso A, Sandstrom A, Zacharewicz E, Mutule I, Suna E, Spura J, Ditrychova K, Stoddart LA, Holliday ND, Wright SC, Lauschke VM, Nielsen S, Scheele C, Cheesman E, Hoeks J, Molenaar P, Summers RJ, Pelcman B, Yakala GK, Bengtsson T. Talamonti E, et al. Among authors: bengtsson t. Mol Metab. 2024 Jul;85:101931. doi: 10.1016/j.molmet.2024.101931. Epub 2024 May 17. Mol Metab. 2024. PMID: 38796310 Free PMC article.
278 results